🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Hepatocellular Carcinoma

Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC NCT06876753n/a2 sites📍 Nanjing📍 Nanjing Zhongda Hospital The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors NCT07159048NA1 site📍 Shanghai Fudan University · Tests: Multimodal Tumor Thermal Therapy System, Radiofrequency Ablation System or Microwave Ablation System Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC NCT07500220Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer NCT07174570Phase 24 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure NCT07219459Phase 223 sites📍 Irvine📍 Los Angeles📍 Orange CatalYm GmbH · Tests: Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma NCT04634357Phase 1, Phase 24 sites📍 Los Angeles📍 Orange📍 San Francisco Eureka Therapeutics Inc. · Tests: ET140203 T Cells Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors NCT06179602n/a1 site📍 Leiden Leiden University Medical Center FGF19 Overexpression Combination Unified Study in HCC-19 NCT06978933Phase 21 site📍 Shanghai RenJi Hospital · Tests: ABSK-011 Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer NCT02174549Phase 1, Phase 22 sites📍 Palo Alto📍 Philadelphia Teclison Ltd. · Tests: Tirapazamine, Conventional Transarterial Embolization (TAE) IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 NCT07303712n/a1 site📍 Palo Alto Palo Alto Veterans Institute for Research A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC NCT04864054Phase 1, Phase 28 sites📍 Duarte📍 Westwood📍 Buffalo Eureka Therapeutics Inc. · Tests: ECT204 T cells Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma NCT03895359Phase 31 site📍 London London Health Sciences Centre Research Institute OR Lawson … · Tests: Stereotactic Body Radiation, Transarterial Chemoembolization Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance NCT07636148n/a3 sites📍 Lyon📍 Créteil📍 Leiden Mark C Burgmans, MD PhD Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations NCT06915753Phase 116 sites📍 Los Angeles📍 San Francisco📍 Stanford Tyra Biosciences, Inc · Tests: TYRA-430 Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors NCT07523529Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide TARGETed Therapy Drug MONITOring in DIGestive Oncology NCT05443087NA29 sites📍 Amiens📍 Auxerre📍 Avignon UNICANCER · Tests: Blood sampling to build population pharmacokinetics model Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017Phase 111 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles Nammi Therapeutics Inc · Tests: QXL138AM Injection every 2 weeks by IV Infusion Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505Phase 11 site📍 Adelaide SAPU NANO (US) LLC · Tests: Sapu003, Exemestane 25 MG Liver Embolization Approaches for Tumor Management NCT05714124n/a1 site📍 Milan IRCCS San Raffaele · Tests: Embolization A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors NCT03432806n/a4 sites📍 Basking Ridge📍 Commack📍 Harrison Memorial Sloan Kettering Cancer Center · Tests: blood draws, colectomy or hepatectomy, Fibroscan test A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors NCT05914116Phase 1, Phase 2107 sites📍 Tucson📍 Los Angeles📍 Los Angeles DualityBio Inc. · Tests: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 NCT06887348n/a2 sites📍 La Jolla📍 Southport Replimune, Inc. · Tests: Observational study with no interventions FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264Phase 1, Phase 233 sites📍 Phoenix📍 Scottsdale📍 Tucson Parabilis Medicines, Inc. · Tests: FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers NCT04221893NA2 sites📍 San Francisco📍 Walnut Creek University of California, San Francisco · Tests: Radiation Therapy (RT) CHARM Hepatocellular Carcinoma MEA Study NCT07650773n/a17 sites📍 Al Mansurah📍 Dakahlia📍 Damietta AstraZeneca First in Human Study of SIM0610 in Solid Tumors NCT07348211Phase 17 sites📍 Chongqing📍 Harbin📍 Shenyang Jiangsu Simcere Pharmaceutical Co., Ltd. · Tests: SIM0610 for Injection, SIM0610 for Injection Scout Dose of Resin Microspheres NCT07476651NA1 site📍 Seoul Seoul National University Hospital · Tests: scout dose
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy